The mechanisms by which haemoglobin inhibits the relaxation of rabbit aorta induced by nitrovasodilators, nitric oxide, or bovine retractor penis inhibitory factor.
The mechanisms by which haemoglobin and methaemoglobin inhibit the vasodilator actions of glyceryl trinitrate, sodium azide, nitric oxide, and the bovine retractor penis inhibitory factor (IF) were studied on rabbit endothelium-denuded aortic rings. Methaemoglobin was less effective than haemoglobin against each vasodilator, it was more effective at inhibiting the relaxation to azide than that to glyceryl trinitrate. Glyceryl trinitrate was neither bound nor inactivated when passed through columns of haemoglobin-agarose or methaemoglobin-agarose. Azide was reversibly bound but less by haemoglobin-agarose than by methaemoglobin-agarose. Inhibition of the vasodilator actions of glyceryl trinitrate is not attributable therefore to a direct interaction with the haemoproteins, although a small part of the inhibition of azide-induced relaxation by methaemoglobin is likely to be due to a direct interaction. Columns of haemoglobin-agarose were more effective than columns of methaemoglobin-agarose in removing nitric oxide from solution. The greater ability of haemoglobin, compared to methaemoglobin, to inhibit vasodilatation induced by nitrovasodilators may therefore reflect the greater ability of haemoglobin to bind nitric oxide which is the active principle of the nitrovasodilators. Neither the acid-activated nor the inactive forms of IF were bound or inactivated when passed through columns of methaemoglobin-agarose. Neither form of IF was retained on passage through columns of haemoglobin-agarose, but the resulting activity in the eluates was less than control, was unstable and, unlike the original activity, decayed rapidly on ice. The greater ability of haemoglobin, compared to methaemoglobin, to inhibit vasodilatation induced by IF might therefore reflect the greater ability of haemoglobin to interact with this vasodilator and inactivate it.
D000818:Animals; D001011:Aorta / Q000187:drug effects; D001386:Azides / Q000037:antagonists & inhibitors; D001685:Biological Factors; D001688:Biological Products / Q000037:antagonists & inhibitors*; D006454:Hemoglobins / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D008706:Methemoglobin / Q000494:pharmacology; D009124:Muscle Proteins / Q000037:antagonists & inhibitors*; D009569:Nitric Oxide / Q000037:antagonists & inhibitors*; D005996:Nitroglycerin / Q000037:antagonists & inhibitors; D011817:Rabbits; D012685:Sepharose; D019810:Sodium Azide; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000037:antagonists & inhibitors*
D001386:Azides; D001685:Biological Factors; D001688:Biological Products; D006454:Hemoglobins; D009124:Muscle Proteins; D014665:Vasodilator Agents; D009569:Nitric Oxide; C033031:smooth muscle inhibitory factor; D008706:Methemoglobin; D012685:Sepharose; D019810:Sodium Azide; D005996:Nitroglycerin